Jiangsu Hengrui Medicine
600276.SS
#508
Rank
C$54.93 B
Marketcap
$8.61
Share price
-0.27%
Change (1 day)
4.66%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2024 (TTM): C$1.11 B

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings (TTM) are C$1.11 B. In 2023 the company made an earning of C$0.89 B an increase over its 2022 earnings that were of C$0.80 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) C$1.11 B24.44%
2023 C$0.89 B11.4%
2022 C$0.80 B-13.65%
2021 C$0.93 B-34.21%
2020 C$1.41 B15.95%
2019 C$1.21 B33.03%
2018 C$0.91 B20.89%
2017 C$0.75 B23.89%
2016 C$0.61 B11.21%
2015 C$0.55 B39.5%
2014 C$0.39 B20.61%
2013 C$0.32 B11.46%
2012 C$0.29 B29.7%
2011 C$0.22 B31.16%
2010 C$0.17 B27.92%
2009 C$0.13 B5.8%
2008 C$0.12 B79.95%
2007 C$70.85 M32.89%
2006 C$53.31 M38.19%
2005 C$38.58 M21.56%
2004 C$31.74 M13.95%
2003 C$27.85 M38.06%
2002 C$20.17 M